Autoantibodies targeting G protein-coupled receptors: An evolving history in autoimmunity. Report of the 4th international symposium.

[1]  H. Ochs,et al.  Cross‐sectional analysis reveals autoantibody signatures associated with COVID‐19 severity , 2023, Journal of medical virology.

[2]  Y. Shoenfeld,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Post-COVID Syndrome: A Common Neuroimmune Ground? , 2022, Diagnostics.

[3]  A. Malkova,et al.  Autoimmune autonomic nervous system imbalance and conditions: Chronic fatigue syndrome, fibromyalgia, silicone breast implants, COVID and post-COVID syndrome, sick building syndrome, post-orthostatic tachycardia syndrome, autoimmune diseases and autoimmune/inflammatory syndrome induced by adjuvants. , 2022, Autoimmunity reviews.

[4]  R. Klein,et al.  Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome. , 2022, Rheumatology.

[5]  Y. Shoenfeld,et al.  Biomarkers in the diagnostic algorithm of myalgic encephalomyelitis/chronic fatigue syndrome , 2022, Frontiers in Immunology.

[6]  A. Goebel,et al.  The biology of symptom-based disorders - Time to act. , 2022, Autoimmunity reviews.

[7]  P. Rosenstiel,et al.  Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19 , 2022, ERJ Open Research.

[8]  F. Paulus,et al.  Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity , 2022, Frontiers in Immunology.

[9]  H. Volk,et al.  Author Correction: A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity , 2022, Nature Communications.

[10]  G. Riemekasten,et al.  Both T and B cells are indispensable for the development of a PBMC transfer-induced humanized mouse model for SSc , 2022, Arthritis Research & Therapy.

[11]  T. Harrer,et al.  Long COVID: Association of Functional Autoantibodies against G-Protein-Coupled Receptors with an Impaired Retinal Microcirculation , 2022, International journal of molecular sciences.

[12]  Y. Shoenfeld,et al.  Cognitive Impairment, Sleep Disturbance, and Depression in Women with Silicone Breast Implants: Association with Autoantibodies against Autonomic Nervous System Receptors , 2022, Biomolecules.

[13]  G. Wallukat,et al.  Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching , 2022, Annals of the Rheumatic Diseases.

[14]  J. van den Born,et al.  Antigen and Cell-Based Assays for the Detection of Non-HLA Antibodies , 2022, Frontiers in Immunology.

[15]  V. Ryabkova,et al.  Intravenouse immunoglobuline in dysautonomia. , 2022, Clinical immunology.

[16]  M. Szczepek,et al.  Angiotensin and Endothelin Receptor Structures With Implications for Signaling Regulation and Pharmacological Targeting , 2022, Frontiers in Endocrinology.

[17]  M. Endres,et al.  Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke , 2022, Circulation research.

[18]  S. Dowell,et al.  Molecular Effects of Auto-Antibodies on Angiotensin II Type 1 Receptor Signaling and Cell Proliferation , 2022, International journal of molecular sciences.

[19]  H. Jumaa,et al.  Autoreactive antibodies control blood glucose by regulating insulin homeostasis , 2022, Proceedings of the National Academy of Sciences.

[20]  D. Kamińska,et al.  Non-HLA Antibodies in Hand Transplant Recipients Are Connected to Multiple Acute Rejection Episodes and Endothelial Activation , 2022, Journal of clinical medicine.

[21]  G. Wallukat,et al.  Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance , 2022, bioRxiv.

[22]  G. Riemekasten,et al.  A broad look into the future of systemic sclerosis , 2022, Therapeutic advances in musculoskeletal disease.

[23]  M. Endres,et al.  Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B) , 2020, Journal of Neurology.

[24]  P. Scheerer,et al.  Autoantibodies Targeting AT1- and ETA-Receptors Link Endothelial Proliferation and Coagulation via Ets-1 Transcription Factor , 2021, International journal of molecular sciences.

[25]  T. Harrer,et al.  Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection , 2021, Frontiers in Medicine.

[26]  B. Paiva,et al.  Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome , 2021, Frontiers in Immunology.

[27]  K. Budde,et al.  Autoantibodies from Patients with Scleroderma Renal Crisis Promote PAR-1 Receptor Activation and IL-6 Production in Endothelial Cells , 2021, International journal of molecular sciences.

[28]  A. Kusch,et al.  Non-HLA antibodies targeting angiotensin II type 1 receptors and endothelin-1 type A receptors impair endothelial repair via a β2-arrestin link to the mTOR pathway. , 2021, Kidney international.

[29]  C. Scheibenbogen,et al.  Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome , 2021, Journal of clinical medicine.

[30]  J. Silverberg,et al.  Association of Varying Clinical Manifestations and Positive Anti–SARS-CoV-2 IgG Antibodies: A Cross-Sectional Observational Study , 2021, The Journal of Allergy and Clinical Immunology: In Practice.

[31]  U. Schlötzer-Schrehardt,et al.  Retinal Microcirculation as a Correlate of a Systemic Capillary Impairment After Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2021, Frontiers in Medicine.

[32]  G. Riemekasten,et al.  Transfer of PBMC From SSc Patients Induces Autoantibodies and Systemic Inflammation in Rag2-/-/IL2rg-/- Mice , 2021, Frontiers in Immunology.

[33]  M. Pallen,et al.  SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse , 2021, Nature Microbiology.

[34]  A. Lichtman.  Anti-body antibodies in COVID-19 , 2021, Science Immunology.

[35]  Shuangge Ma,et al.  Diverse functional autoantibodies in patients with COVID-19 , 2021, Nature.

[36]  H. Prüss.  Autoantibodies in neurological disease , 2021, Nature Reviews Immunology.

[37]  X. Mariette,et al.  Systemic and organ-specific immune-related manifestations of COVID-19 , 2021, Nature Reviews Rheumatology.

[38]  G. Wallukat,et al.  Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms , 2021, Journal of Translational Autoimmunity.

[39]  Guido Moll,et al.  Transcriptional Regulation of Thrombin-Induced Endothelial VEGF Induction and Proangiogenic Response , 2021, Cells.

[40]  Y. Shoenfeld,et al.  Autoimmune dysautonomia in women with silicone breast implants. , 2021, Journal of autoimmunity.

[41]  J. Silverberg,et al.  SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United States , 2021, JAMA network open.

[42]  M. Leboyer,et al.  DNA hydrolysing IgG catalytic antibodies: an emerging link between psychoses and autoimmunity , 2021, npj Schizophrenia.

[43]  Y. Shoenfeld,et al.  The SARS-CoV-2 as an instrumental trigger of autoimmunity , 2021, Autoimmunity Reviews.

[44]  J. Guck,et al.  Physical phenotype of blood cells is altered in COVID-19 , 2021, bioRxiv.

[45]  G. Klintmalm,et al.  Non-HLA Autoantibodies at 1 Year Negatively Affect 5-Year Native Renal Function in Liver Transplant Recipients. , 2021, Transplantation proceedings.

[46]  P. Borrow,et al.  Targeting autoantibodies in COVID-19 , 2021, Nature Reviews Immunology.

[47]  H. Ljunggren,et al.  High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19 , 2021, Proceedings of the National Academy of Sciences.

[48]  Roxanne Khamsi.  Rogue antibodies could be driving severe COVID-19 , 2021, Nature.

[49]  G. Riemekasten,et al.  Autoantibodies against C5aR1, C3aR1, CXCR3, and CXCR4 are decreased in primary Sjogren's syndrome. , 2021, Molecular immunology.

[50]  G. Wallukat,et al.  Agonistic β2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma , 2020, Frontiers in Immunology.

[51]  Y. Shoenfeld,et al.  SARS-CoV-2, the autoimmune virus , 2020, Autoimmunity Reviews.

[52]  Samuel M. Brown,et al.  Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study , 2020, The Lancet Rheumatology.

[53]  Steven M. Holland,et al.  Autoantibodies against type I IFNs in patients with life-threatening COVID-19 , 2020, Science.

[54]  C. Scheibenbogen,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat Immunoadsorption , 2020, Journal of clinical medicine.

[55]  D. Goldstein,et al.  The extended autonomic system, dyshomeostasis, and COVID-19 , 2020, Clinical Autonomic Research.

[56]  J. Bergquist,et al.  Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients – A validation study in plasma and cerebrospinal fluid from two Swedish cohorts , 2020, Brain, behavior, & immunity - health.

[57]  A. Vojdani,et al.  Antibodies against Group A Streptococcus, dopamine receptors, and ganglioside GM1 cross-react with a variety of food antigens, potentially interfering with biomarkers for PANS and PANDAS , 2020 .

[58]  H. Krumholz,et al.  Extrapulmonary manifestations of COVID-19 , 2020, Nature Medicine.

[59]  H. Matsuda,et al.  Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome , 2020, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[60]  A. Bramanti,et al.  Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review) , 2020, International journal of molecular medicine.

[61]  M. Ehrenfeld,et al.  Covid-19 and autoimmunity , 2020, Autoimmunity Reviews.

[62]  J. Bayry,et al.  Autoimmune and inflammatory diseases following COVID-19 , 2020, Nature Reviews Rheumatology.

[63]  Y. Qadri,et al.  Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19 , 2020, Journal of Cardiovascular Translational Research.

[64]  S. Athey,et al.  Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. , 2020, The Journal of clinical investigation.

[65]  C. Scheibenbogen,et al.  A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors. , 2020, Autoimmunity reviews.

[66]  J. Chapman,et al.  Complex syndromes of chronic pain, fatigue and cognitive impairment linked to autoimmune dysautonomia and small fiber neuropathy. , 2020, Clinical immunology.

[67]  A. M. Leontovich,et al.  The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.

[68]  C. Meisel,et al.  IgG stimulated β2 adrenergic receptor activation is attenuated in patients with ME/CFS , 2020, Brain, behavior, & immunity - health.

[69]  L. A. Dempsey.  Pathogenic antibodies , 2019, Nature Immunology.

[70]  Y. Shoenfeld,et al.  Neuroimmunology: What Role for Autoimmunity, Neuroinflammation, and Small Fiber Neuropathy in Fibromyalgia, Chronic Fatigue Syndrome, and Adverse Events after Human Papillomavirus Vaccination? , 2019, International journal of molecular sciences.

[71]  G. Wallukat,et al.  Autoantibodies Activating the β2-Adrenergic Receptor Characterize Patients With Primary and Secondary Glaucoma , 2019, Front. Immunol..

[72]  M. Endres,et al.  Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). , 2019, Stroke.

[73]  M. Uhlén,et al.  Multiplexed analysis of the secretin-like GPCR-RAMP interactome , 2019, Science Advances.

[74]  M. Benros,et al.  Autoimmune Diseases and Psychotic Disorders , 2019, Front. Psychiatry.

[75]  J. Aguillón,et al.  Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies , 2019, Front. Immunol..

[76]  Jeffrey H. Meyer,et al.  Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. , 2020, The lancet. Psychiatry.

[77]  G. Riemekasten,et al.  Loss of balance in normal GPCR-mediated cell trafficking. , 2019, Frontiers in bioscience.

[78]  K. Kinzler,et al.  Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome , 2018, Nature.

[79]  B. Engelhardt,et al.  GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis , 2018, Nature Communications.

[80]  Y. Shoenfeld,et al.  Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis. , 2018, International journal of epidemiology.

[81]  Hui Zheng,et al.  Peripheral immune system in aging and Alzheimer’s disease , 2018, Molecular Neurodegeneration.

[82]  A. Vojdani,et al.  Amyloid-Beta 1-42 Cross-Reactive Antibody Prevalent in Human Sera May Contribute to Intraneuronal Deposition of A-Beta-P-42 , 2018, International journal of Alzheimer's disease.

[83]  G. Riemekasten,et al.  Autoantibodies against muscarinic acetylcholine receptor M3 in Sjogren's syndrome and corresponding mouse models. , 2018, Frontiers in bioscience.

[84]  C. Scheibenbogen,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease. , 2018, Autoimmunity reviews.

[85]  F. Petersen,et al.  A methodological review of induced animal models of autoimmune diseases. , 2018, Autoimmunity reviews.

[86]  H. Volk,et al.  Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME , 2018, PloS one.

[87]  G. Wallukat,et al.  Agonistic Autoantibodies to the β2-Adrenergic Receptor Involved in the Pathogenesis of Open-Angle Glaucoma , 2018, Front. Immunol..

[88]  G. Gilkeson,et al.  Mouse models of lupus: what they tell us and what they don’t , 2018, Lupus Science & Medicine.

[89]  J. Chan,et al.  A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice , 2017, Scientific Reports.

[90]  G. Riemekasten,et al.  Functional autoantibodies targeting G protein-coupled receptors in rheumatic diseases , 2017, Nature Reviews Rheumatology.

[91]  A. Verkman,et al.  Mechanisms of Autoantibody-Induced Pathology , 2017, Front. Immunol..

[92]  D. Aarsland,et al.  Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. , 2017, Journal of Alzheimer's disease : JAD.

[93]  D. Dragun,et al.  Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. , 2016, Kidney international.

[94]  G. Riemekasten,et al.  Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis. , 2016, Autoimmunity reviews.

[95]  Mats Nilsson,et al.  Multiplexed protein profiling by sequential affinity capture , 2016, Proteomics.

[96]  C. Meisel,et al.  Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome , 2016, Brain, Behavior, and Immunity.

[97]  J. Hong,et al.  Serotonin 6 receptor controls alzheimer’s disease and depression , 2015, Oncotarget.

[98]  Ø. Fluge,et al.  B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment , 2015, PloS one.

[99]  J. Wiltfang,et al.  Preexisting Serum Autoantibodies Against the NMDAR Subunit NR1 Modulate Evolution of Lesion Size in Acute Ischemic Stroke , 2015, Stroke.

[100]  B. Winblad,et al.  Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[101]  Bharat B. Biswal,et al.  High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types , 2014, Annals of clinical and translational neurology.

[102]  S. Tunaru,et al.  A novel luminescence‐based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients' sera , 2014, Clinical and experimental immunology.

[103]  J. Macdonald,et al.  Recent Progress in Understanding Subtype Specific Regulation of NMDA Receptors by G Protein Coupled Receptors (GPCRs) , 2014, International journal of molecular sciences.

[104]  J. Leckman,et al.  Brain Human Monoclonal Autoantibody from Sydenham Chorea Targets Dopaminergic Neurons in Transgenic Mice and Signals Dopamine D2 Receptor: Implications in Human Disease , 2013, The Journal of Immunology.

[105]  Martin Dichgans,et al.  Prediction of Vascular Risk after Stroke — Protocol and Pilot Data of the Prospective Cohort with Incident Stroke (PROSCIS) , 2013, International journal of stroke : official journal of the International Stroke Society.

[106]  D. Dragun,et al.  Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance , 2013, Current opinion in organ transplantation.

[107]  Robert G. Nagele,et al.  Natural IgG Autoantibodies Are Abundant and Ubiquitous in Human Sera, and Their Number Is Influenced By Age, Gender, and Disease , 2013, PloS one.

[108]  M. Babu,et al.  Molecular signatures of G-protein-coupled receptors , 2013, Nature.

[109]  A. Kusch,et al.  Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection. , 2012, Human immunology.

[110]  D. Dragun,et al.  Role of non-HLA antibodies in organ transplantation , 2012, Current opinion in organ transplantation.

[111]  G. Wallukat,et al.  Renal Ischemia and Transplantation Predispose to Vascular Constriction Mediated by Angiotensin II Type 1 Receptor-Activating Antibodies , 2012, Transplantation.

[112]  N. Pfeiffer,et al.  Effect of Ischemia Duration on Autoantibody Response in Rats Undergoing Retinal Ischemia-Reperfusion , 2012, Ophthalmic Research.

[113]  D. Drossman,et al.  Anti-Enteric Neuronal Antibodies and the Irritable Bowel Syndrome , 2012, Journal of neurogastroenterology and motility.

[114]  Kaleb M. Pauley,et al.  Animal Models in Autoimmune Diseases: Lessons Learned from Mouse Models for Sjögren’s Syndrome , 2012, Clinical Reviews in Allergy & Immunology.

[115]  Y. Shoenfeld,et al.  Explosion of autoimmune diseases and the mosaic of old and novel factors , 2011, Cellular and Molecular Immunology.

[116]  T. Slowinski,et al.  Involvement of functional autoantibodies against vascular receptors in systemic sclerosis , 2010, Annals of the rheumatic diseases.

[117]  R. Falk,et al.  The rise and fall of horror autotoxicus and forbidden clones. , 2010, Kidney international.

[118]  Y. Shoenfeld,et al.  Clinical and Molecular Evidence for Association of SLE with parvovirus B19 , 2010, Lupus.

[119]  I. Mackay.  Travels and travails of autoimmunity: a historical journey from discovery to rediscovery. , 2010, Autoimmunity reviews.

[120]  B. Hegner,et al.  Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies , 2009, Thrombosis and Haemostasis.

[121]  M. Frémont,et al.  Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients. , 2009, In vivo.

[122]  H. Lutz,et al.  Naturally occurring auto-antibodies in homeostasis and disease. , 2009, Trends in immunology.

[123]  Bin Wang,et al.  Vascular Damages in Rats Immunized by α1-Adrenoceptor Peptides , 2008, Cellular and Molecular Immunology.

[124]  Y. Shoenfeld,et al.  Hepatitis B Virus (HBV) and Autoimmune Disease , 2008, Clinical reviews in allergy & immunology.

[125]  Y. Shoenfeld,et al.  Epstein–Barr Virus and Cytomegalovirus in Autoimmune Diseases , 2007, Annals of the New York Academy of Sciences.

[126]  J. Macdonald,et al.  G protein-coupled receptors control NMDARs and metaplasticity in the hippocampus. , 2007, Biochimica et biophysica acta.

[127]  Josep Dalmau,et al.  Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma , 2007, Annals of neurology.

[128]  O. Parnes.  Autoimmune disease , 2006, The Lancet.

[129]  Erik K. Malm,et al.  A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics* , 2005, Molecular & Cellular Proteomics.

[130]  J. Wetzels,et al.  Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. , 2005, The New England journal of medicine.

[131]  L. Morel.  Mouse Models of Human Autoimmune Diseases: Essential Tools That Require the Proper Controls , 2004, PLoS biology.

[132]  A. Annoni,et al.  Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor α-Subunit Induces Experimental Myasthenia Gravis in Rats 1 , 2004, The Journal of Immunology.

[133]  T. Takano,et al.  Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. , 2003, International journal of molecular medicine.

[134]  P. Lipsky,et al.  Autoantibodies as predictors of disease. , 2001, The Journal of clinical investigation.

[135]  J. Friedman,et al.  Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[136]  J. Lipski,et al.  An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. , 2000, Science.

[137]  I. Fajardy,et al.  Coxsackie B virus infection and beta cell autoantibodies in newly diagnosed IDDM adult patients. , 1998, Clinical and diagnostic virology.

[138]  D. Buchwald,et al.  Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. , 1996, The Journal of clinical investigation.

[139]  E. Borda,et al.  Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome , 1996, Clinical and experimental immunology.

[140]  R. Klein,et al.  High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. , 1995, European journal of medical research.

[141]  H. Niznik,et al.  The Dopamine D1D Receptor , 1995, The Journal of Biological Chemistry.

[142]  G. Wallukat,et al.  Supersensitivity to beta-adrenoceptor stimulation evoked in cultured neonatal rat heart myocytes by L(+)-lactate and pyruvate. , 1993, Journal of autonomic pharmacology.

[143]  H. Jampel,et al.  Beta-adrenergic receptors in human trabecular meshwork. Identification and autoradiographic localization. , 1987, Investigative ophthalmology & visual science.

[144]  P. Molinoff,et al.  Distribution and properties of beta-adrenergic receptors in human iris-ciliary body. , 1987, Investigative ophthalmology & visual science.

[145]  G. Wallukat,et al.  Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. , 1987, Biomedica biochimica acta.

[146]  J. Dacie,et al.  Autoimmune haemolytic anaemias. , 1970, British medical journal.

[147]  A. Szentivanyi.  The beta adrenergic theory of the atopic abnormality in bronchial asthma , 1968 .

[148]  J. Loutit,et al.  Haemolytic icterus (acholuric jaundice) congenital and acquired. , 1946, Lancet.

[149]  P. Ehrlich,et al.  Croonian lecture.—On immunity with special reference to cell life , 1900, Proceedings of the Royal Society of London.